Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Kicks Off Global PIII for Adult X-Linked Hypophosphatemia
December 7, 2015
- Unusualness of Hep C Market Not Being Understood, Gilead COO Says on Possible Sovaldi Re-Pricing
December 4, 2015
- Nichi-Iko Sells Off Shares Held in South Korean Firm
December 3, 2015
- GSK’s Drug Supplies Disrupted by Manufacturing Woes Overseas
December 2, 2015
- Japan NDA for IBS-C Drug Linaclotide Planned in 2016: Astellas
December 2, 2015
- Sumitomo Dainippon to Reinstate Hara as Drug Development Head
December 2, 2015
- Daiichi Sankyo to Shutter German Biotech Unit amid R&D Cost-Cut Drive
December 2, 2015
- Kyowa Kirin Launches Japan PIII Study for Regpara Successor
December 2, 2015
- Ole Moelskov Bech to Lead Novo Nordisk Japan from January
December 2, 2015
- Heptares Inks R&D Deal with Pfizer; Pfizer to Buy 3% Stake in Sosei for US$33 Million
December 2, 2015
- Takeda to Set Up Generic JV with Teva, Transfer Long-Listed Products
December 1, 2015
- Mitsubishi Tanabe Set to Derive 40% of Sales Abroad in FY2020, Shed 1,200 Jobs over 5 Years
December 1, 2015
- Chris Hourigan Named as New President of Janssen Japan Unit
December 1, 2015
- Takeda, Teva Hook Up to Form Generic Joint Venture in Japan
November 30, 2015
- Eisai to Venture into Chinese Generic Market by Acquiring Local Firm
November 30, 2015
- Takeda’s MS Drug Copaxone Now Available; Actelion to Release Japan’s 1st Pediatric PAH Medicine in January
November 30, 2015
- JCR to Launch Cell Therapy for Post-Transplant Complication in February
November 30, 2015
- Viekirax Hits Japan Market, MHLW Orders Rare Label Revision upon Listing
November 27, 2015
- Eisai to Sell Food & Chemical Biz to Mitsubishi Chemical
November 27, 2015
- Sales of Candesartan AGs Miss Half-Year Target on Azilva Switches: ASKA Chief
November 26, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…